Cargando…

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding

BACKGROUND: Little is published about warfarin therapy adherence patterns beyond 6 months of initial anticoagulant treatment and their association with effectiveness and safety for patients with venous thromboembolism (VTE). OBJECTIVES: To compare the risks of recurrent VTE and major bleeding during...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hye-Rim, Jones, Bobby L., Lo-Ciganic, Wei-Hsuan, DeRemer, Christina E., Dietrich, Eric A., Huang, Pei-Lin, Park, Haesuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163671/
https://www.ncbi.nlm.nih.gov/pubmed/37159747
http://dx.doi.org/10.1016/j.rpth.2023.100131
_version_ 1785037931679842304
author Kang, Hye-Rim
Jones, Bobby L.
Lo-Ciganic, Wei-Hsuan
DeRemer, Christina E.
Dietrich, Eric A.
Huang, Pei-Lin
Park, Haesuk
author_facet Kang, Hye-Rim
Jones, Bobby L.
Lo-Ciganic, Wei-Hsuan
DeRemer, Christina E.
Dietrich, Eric A.
Huang, Pei-Lin
Park, Haesuk
author_sort Kang, Hye-Rim
collection PubMed
description BACKGROUND: Little is published about warfarin therapy adherence patterns beyond 6 months of initial anticoagulant treatment and their association with effectiveness and safety for patients with venous thromboembolism (VTE). OBJECTIVES: To compare the risks of recurrent VTE and major bleeding during extended treatment between adherence patterns using MarketScan Commercial and Medicare Supplemental databases (2013-2019). METHODS: In a retrospective cohort study, we included patients with incident VTE who completed an initial 6-month anticoagulant treatment and received either warfarin or no extended therapy. Group-based trajectory models were used to identify distinct extended treatment trajectories. Associations between the trajectories and risk of hospitalization due to recurrent VTE and major bleeding were assessed using inverse probability treatment-weighted Cox proportional hazards models. RESULTS: Compared with no extended treatment, consistently high warfarin adherence was associated with a significantly decreased risk of hospitalization due to recurrent VTE (hazard ratio [HR] = 0.23; 95% CI, 0.12-0.45), but gradually (HR = 0.29; 95CI, 0.08-1.06) or rapidly declining (HR = 0.14; 95% CI, 0.02-1.24) adherence showed no association with the risk of hospitalization due to recurrent VTE. Compared with no extended treatment, warfarin extended therapy was associated with an increased risk of hospitalization due to major bleeding regardless of adherence patterns (consistently high: HR = 2.08; 95% CI, 1.18-3.64, gradually declining: HR = 2.10; 95% CI, 0.74-5.95, and rapidly declining: HR = 9.19; 95% CI, 4.38-19.29). However, compared with rapidly declining adherence, consistently high (HR = 0.23; 95% CI, 0.11-0.47) and gradually declining (HR = 0.23; 95% CI, 0.08-0.64) adherence were associated with decreased risk of hospitalization due to major bleeding. CONCLUSION: The findings indicated that consistently high adherence to extended warfarin treatment was associated with a decreased risk of hospitalization due to recurrent VTE but an increased risk of hospitalization due to major bleeding compared with no extended treatment.
format Online
Article
Text
id pubmed-10163671
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101636712023-05-07 Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding Kang, Hye-Rim Jones, Bobby L. Lo-Ciganic, Wei-Hsuan DeRemer, Christina E. Dietrich, Eric A. Huang, Pei-Lin Park, Haesuk Res Pract Thromb Haemost Brief Report BACKGROUND: Little is published about warfarin therapy adherence patterns beyond 6 months of initial anticoagulant treatment and their association with effectiveness and safety for patients with venous thromboembolism (VTE). OBJECTIVES: To compare the risks of recurrent VTE and major bleeding during extended treatment between adherence patterns using MarketScan Commercial and Medicare Supplemental databases (2013-2019). METHODS: In a retrospective cohort study, we included patients with incident VTE who completed an initial 6-month anticoagulant treatment and received either warfarin or no extended therapy. Group-based trajectory models were used to identify distinct extended treatment trajectories. Associations between the trajectories and risk of hospitalization due to recurrent VTE and major bleeding were assessed using inverse probability treatment-weighted Cox proportional hazards models. RESULTS: Compared with no extended treatment, consistently high warfarin adherence was associated with a significantly decreased risk of hospitalization due to recurrent VTE (hazard ratio [HR] = 0.23; 95% CI, 0.12-0.45), but gradually (HR = 0.29; 95CI, 0.08-1.06) or rapidly declining (HR = 0.14; 95% CI, 0.02-1.24) adherence showed no association with the risk of hospitalization due to recurrent VTE. Compared with no extended treatment, warfarin extended therapy was associated with an increased risk of hospitalization due to major bleeding regardless of adherence patterns (consistently high: HR = 2.08; 95% CI, 1.18-3.64, gradually declining: HR = 2.10; 95% CI, 0.74-5.95, and rapidly declining: HR = 9.19; 95% CI, 4.38-19.29). However, compared with rapidly declining adherence, consistently high (HR = 0.23; 95% CI, 0.11-0.47) and gradually declining (HR = 0.23; 95% CI, 0.08-0.64) adherence were associated with decreased risk of hospitalization due to major bleeding. CONCLUSION: The findings indicated that consistently high adherence to extended warfarin treatment was associated with a decreased risk of hospitalization due to recurrent VTE but an increased risk of hospitalization due to major bleeding compared with no extended treatment. Elsevier 2023-03-27 /pmc/articles/PMC10163671/ /pubmed/37159747 http://dx.doi.org/10.1016/j.rpth.2023.100131 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Report
Kang, Hye-Rim
Jones, Bobby L.
Lo-Ciganic, Wei-Hsuan
DeRemer, Christina E.
Dietrich, Eric A.
Huang, Pei-Lin
Park, Haesuk
Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title_full Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title_fullStr Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title_full_unstemmed Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title_short Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
title_sort trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163671/
https://www.ncbi.nlm.nih.gov/pubmed/37159747
http://dx.doi.org/10.1016/j.rpth.2023.100131
work_keys_str_mv AT kanghyerim trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT jonesbobbyl trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT lociganicweihsuan trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT deremerchristinae trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT dietricherica trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT huangpeilin trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding
AT parkhaesuk trajectoriesofadherencetoextendedtreatmentwithwarfarinandrisksofrecurrentvenousthromboembolismandmajorbleeding